



MEETING ABSTRACT

Open Access

Efficacy and safety of fluticasone furoate nasal spray in adult and adolescent subjects with uncomplicated acute rhinosinusitis

Paul Keith^{1*}, Andrzej Dymek², Oliver Pfaar³, Wytke Fokkens⁴, Nazli Topors⁵, Wei Wu⁶, Suyong Yun Kirby⁶, Laurie A Lee⁶

From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2011 Quebec, Canada. 20-23 October 2011

Background

Uncomplicated acute rhinosinusitis (ARS) is usually a self-limiting inflammatory condition often treated with antibiotics. This study evaluated an alternative treatment for symptomatic relief of uncomplicated ARS, fluticasone furoate nasal spray (FFNS).

Methods

This randomized, double-blind, placebo-controlled, parallel-group, multicenter, 2-week treatment study evaluated FFNS 110 mcg once daily, twice daily vs. placebo in adults/adolescents with uncomplicated ARS. Eligibility criteria reflected a clinical diagnosis and eliminated confounding conditions like common cold, symptomatic allergic rhinitis (AR), and other sinonasal conditions. Subjects with daily major symptom score (MSS; a composite score of 3 symptoms [nasal congestion/stuffiness, sinus headache/pressure or facial pain/pressure, and postnasal drip on a 0-3 scale]) >4.5 at baseline were randomized.

Results

The study demonstrated a statistically significant reduction in daily MSS by both FFNS doses compared to placebo (LS mean differences vs. placebo of -0.357 [p=0.014] and -0.386 [p=0.008] for BID and QD, respectively). The differences in median time to symptom improvement between placebo (8 days) and each FFNS dose (7 days) were not statistically significant. There were no treatment differences in antibiotic use due to the development of possible fulminant bacterial rhinosinusitis (3% in each group). The safety profile of FFNS was similar to placebo.

Conclusion

FFNS reduced symptoms of uncomplicated ARS compared to placebo and was well tolerated, providing support for withholding antibiotics in selected patients. (FFR113203/ GSK funded)

Author details

¹McMaster University, Hamilton, ON, Canada. ²Centrum Medyczne Lucyna Andrzej Dymek NZOZ S.C., Poland. ³University Hospital Mannheim, Wiesbaden, Germany. ⁴Academisch Medisch Centrum, Amsterdam, The Netherlands. ⁵GlaxoSmithKline, Mississauga, ON, Canada. ⁶GlaxoSmithKline, Research Triangle Park, NC, USA.

Published: 14 November 2011

doi:10.1186/1710-1492-7-S2-A41

Cite this article as: Keith et al.: Efficacy and safety of fluticasone furoate nasal spray in adult and adolescent subjects with uncomplicated acute rhinosinusitis. *Allergy, Asthma & Clinical Immunology* 2011 **7**(Suppl 2):A41.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹McMaster University, Hamilton, ON, Canada
Full list of author information is available at the end of the article